SPY415.87+4.42 1.07%
DIA340.44+2.91 0.86%
IXIC14,038.76+180.92 1.31%

BRIEF-Sangamo Therapeutics Sangamo Says EMA Releases Details Supporting Orphan Designation For BIVV003 For Treatment Of Sickle Cell Disease

· 03/17/2021 16:42
BRIEF-Sangamo Therapeutics Sangamo Says EMA Releases Details Supporting Orphan Designation For BIVV003 For Treatment Of Sickle Cell Disease

- Sangamo Therapeutics Inc SGMO.O:

  • SANGAMO ANNOUNCES EMA RELEASES DETAILS SUPPORTING ORPHAN DESIGNATION FOR BIVV003 FOR TREATMENT OF SICKLE CELL DISEASE

Source text for Eikon: ID:nBwbX4XxRa

Further company coverage: SGMO.O


((Reuters.Briefs@thomsonreuters.com;))